Compare CURR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | GLSI |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.8M | 236.2M |
| IPO Year | 2021 | 2020 |
| Metric | CURR | GLSI |
|---|---|---|
| Price | $1.88 | $19.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | ★ 243.0K | 196.2K |
| Earning Date | 12-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,435,412.00 | N/A |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $7.78 |
| 52 Week High | $5.08 | $34.10 |
| Indicator | CURR | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 57.05 |
| Support Level | $1.43 | $14.07 |
| Resistance Level | $3.50 | $19.36 |
| Average True Range (ATR) | 0.23 | 1.76 |
| MACD | 0.03 | 0.44 |
| Stochastic Oscillator | 64.18 | 64.42 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It operates into two reportable segments, which are remittance services and sales of airtime, of which maximum revenue is generated from the Remittance segment. Geographically, the group generates the majority of its geographic revenue from Malaysia.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.